Oppenheimer Reiterates “Outperform” Rating for enGene (NASDAQ:ENGN)

Oppenheimer reiterated their outperform rating on shares of enGene (NASDAQ:ENGN) in a research report released on Tuesday, Benzinga reports. The brokerage currently has a $30.00 price objective on the stock.

Separately, Morgan Stanley reissued an overweight rating and issued a $40.00 target price on shares of enGene in a research note on Wednesday, September 11th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of Buy and an average target price of $33.67.

enGene Stock Up 10.0 %

Shares of ENGN opened at $6.05 on Tuesday. The company has a 50-day simple moving average of $7.06 and a 200-day simple moving average of $10.89. The firm has a market capitalization of $267.20 million, a P/E ratio of -3.65 and a beta of -0.68. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. enGene has a 52 week low of $4.42 and a 52 week high of $43.00.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. On average, equities research analysts expect that enGene will post -1.64 earnings per share for the current year.

Institutional Trading of enGene

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Altitude Crest Partners Inc. bought a new stake in enGene in the first quarter valued at about $2,039,000. SR One Capital Management LP bought a new stake in enGene during the second quarter worth about $4,715,000. Omega Fund Management LLC bought a new stake in enGene during the fourth quarter worth about $10,441,000. Logos Global Management LP grew its stake in enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in enGene during the first quarter worth about $17,095,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.